Objective: Rewiring of excitatory glutamatergic neuronal circuits is a major abnormality in epilepsy. Besides the rewiring of excitatory circuits, an abnormal depolarizing c-aminobutyric acidergic (GABAergic) drive has been hypothesized to participate in the epileptogenic processes. However, a remaining clinically relevant question is whether early post-status epilepticus (SE) evoked chloride dysregulation is important for the remodeling of aberrant glutamatergic neuronal circuits. Methods: Osmotic minipumps were used to infuse intracerebrally a specific inhibitor of depolarizing GABAergic transmission as well as a functionally blocking antibody toward the pan-neurotrophin receptor p75 (p75 NTR ). The compounds were infused between 2 and 5 days after pilocarpine-induced SE. Immunohistochemistry for NKCC1, KCC2, and ectopic recurrent mossy fiber (rMF) sprouting as well as telemetric electroencephalographic and electrophysiological recordings were performed at day 5 and 2 months post-SE. Results: Blockade of NKCC1 after SE with the specific inhibitor bumetanide restored NKCC1 and KCC2 expression, normalized chloride homeostasis, and significantly reduced the glutamatergic rMF sprouting within the dentate gyrus. This mechanism partially involves p75 NTR signaling, as bumetanide application reduced SE-induced p75 NTR expression and functional blockade of p75 NTR decreased rMF sprouting. The early transient (3 days) post-SE infusion of bumetanide reduced rMF sprouting and recurrent seizures in the chronic epileptic phase. Interpretation: Our findings show that early post-SE abnormal depolarizing GABA and p75 NTR signaling fosters a long-lasting rearrangement of glutamatergic network that contributes to the epileptogenic process. This finding defines promising and novel targets to constrain reactive glutamatergic network rewiring in adult epilepsy.
expression and functional blockade of p75 NTR decreased rMF sprouting. The early transient (3 days) post-SE infusion of bumetanide reduced rMF sprouting and recurrent seizures in the chronic epileptic phase. Interpretation: Our findings show that early post-SE abnormal depolarizing GABA and p75 NTR signaling fosters a long-lasting rearrangement of glutamatergic network that contributes to the epileptogenic process. This finding defines promising and novel targets to constrain reactive glutamatergic network rewiring in adult epilepsy. ANN NEUROL 2017; 81:251-265 P lastic remodeling of glutamatergic neuronal networks is one of the major pathophysiological processes observed in epileptic tissue and after traumatic brain injury (TBI) in both humans and animal models. 1, 2 The understanding of the molecular mechanisms involved in this plastic remodeling is of particular importance, because it creates a powerful hyperexcitable cerebral focus that drives recurrent disabling seizures. [3] [4] [5] This phenomenon, called reactive plasticity, is well documented in the dentate gyrus (DG), where ectopic dentate granule cell (DGC) axons (the recurrent mossy fibers [rMFs]) sprout and create a reverberant excitatory circuit between DGCs. This is involved in the formation of epileptiform bursts in patients with temporal lobe epilepsy (TLE) and TBI, as well as in animal models. [6] [7] [8] [9] [10] [11] [12] [13] Although the molecular mechanisms are unclear, there is evidence supporting an active role of neurotrophin signaling.
events that activate neurotrophin pathways and trigger the ectopic rMF growth remain elusive. Besides the rewiring of excitatory circuits, an abnormal depolarizing c-aminobutyric acidergic (GABAergic) drive has been hypothesized to participate in epileptogenic processes in adult brain. This includes the dysregulation of the neuronal specific K 1 -Cl 2 cotransporter KCC2 and the Na 1 -
2 cotransporter NKCC1, as reported in resected tissues from human TLE patients 18, 19 and animal models. [20] [21] [22] Bumetanide, a specific blocker of NKCC1, has been shown to have acute anticonvulsant action on chronic epileptic activity. 23 We have also previously
shown that depolarizing GABAergic transmission triggers the upregulation of the pan-neurotrophin receptor p75 (p75NTR) in an acute injury model. 24 Here, we have tested the hypothesis whereby the early alteration of chloride homeostasis following SE is a precipitating event involved in rMF sprouting establishment via the activation of p75 NTR . We examined a novel therapeutic strategy based on the transitory blockade of NKCC1, early after SE (ie, before the appearance of ictal activities), to reduce the ectopic sprouting and recurrent seizures in the chronic epileptic phase (ie, several months after SE). We found that a functional establishment of ectopic rMF sprouting takes place concomitantly with altered expression of NKCC1 and KCC2 as early as day 5 post-SE in the rat pilocarpine model of TLE. Moreover, we were able to demonstrate that p75 NTR is upregulated and is involved in the formation of ectopic rMF sprouting. In turn, NKCC1 inhibition resulted in the decrease of post-SE p75 NTR upregulation and the reduction of rMF sprouting. Finally, transitory blockade of NKCC1 a few days after SE resulted in a significant reduction of rMF growth and recurrent seizures at the chronic stage. In conclusion, our findings pave the way to identify novel therapeutic strategies targeting cation-chloride cotransporters and p75 NTR signaling pathways to constrain abnormal glutamatergic network rewiring and chronic adult epilepsy.
Experimental Procedures
ANIMALS. All experiments were approved by the National Institute of Health and Medical Research through the local ethics committee (project number 66-15112012) and in accordance with European community council directive 2010/63/UE. Adult male Wistar rats had access to food and water ad libitum and were housed under a 12-hour light/dark cycle at 22-24 8C.
RAT MODEL OF TLE. An animal model of TLE was obtained using adult male Wistar rats, as previously described. 25 Briefly, 6-week-old male rats (Charles River Laboratories, Wilmington, MA; Janvier Labs, Le Genest- Table) . After rinsing 3 times in PBS, slices were incubated with the corresponding Alexa Fluor-conjugated secondary antibodies diluted in PBS (1:1,000; Invitrogen, Carlsbad, CA) for 1 hour (SPO was incubated an additional 2 hours) at room temperature and finally counterstained for 5 minutes with Hoechst 33258 (10 lg/ml in PBS, Sigma-Aldrich). Quantification of KCC2 analysis was performed in blind. For plot analysis of KCC2, the intensity and distribution associated with the membrane or cytosolic regions in naive rats, control pilocarpine, pilocarpine vehicle-treated rats, and pilocarpine bumetanide-treated were performed using 320 objective and Plot analysis using Fiji software. The same straight-line length (10 mm) was applied from the nucleus to the external cell compartment of 50 cells from each condition. The plot profile values were analyzed, and the standard error of the mean (SEM) was calculated. The total fluorescence intensity analysis of KCC2 has been normalized to the number of NeuN-positive cells contained in the regions of interest. The Fiji software 3-dimensional object counter plugin was used to count the number of cells.
ACUTE SLICE PREPARATION. Animals were deeply anesthetized with chloral hydrate (350mg/kg, i.p.) and decapitated. The brain was removed rapidly, the hippocampi were dissected, and transverse 400 lm slices were cut in oxygenated (95% O 2 and 5% CO 2 ) modified artificial cerebrospinal fluid (ACSF) containing the following (in millimolars): 132 choline, 2. Hippocampal slices were individually transferred to a recording chamber maintained at 30 to 32 8C and continuously perfused (2ml/min) with oxygenated normal or adapted ACSF containing 5 lM gabazine. Synchronized burst discharges were evoked by antidromic stimulation of the mossy fiber pathway in the CA3b area while recording local field potentials in the dentate granular layer using a DAM-80 amplifier (low filter, 0.1Hz; high pass filter, 3 KHz; World Precision Instruments, Sarasota, FL). Signals were analyzed off-line using Clampfit (pCLAMP 9.2; Molecular Devices, Sunnyvale, CA) and MiniAnalysis 6.0.1 (Synaptosoft, Decatur, GA). Wholecell patch-clamp recordings were done using a MultiClamp 700B amplifier (Molecular Devices). The patch pipette solution contained the following (in millimolars): 18 KCl 2 , 111 K-gluconate, 0.5 CaCl 2 , 2 NaOH, 10 glucose, 10 HEPES, 2 Mg-ATP, and 5 BAPTA (pH adjusted to 7.3 with KOH). Patch pipettes were fabricated from borosilicate glass (Harvard Apparatus, Edenbridge, UK), and their resistance ranged from 6.5 to 7.5MX. Only cells with access resistances between 10 and 20MX were accepted for analysis. Membrane potential was clamped at 60mV. All membrane potential values were corrected for a liquid-junction potential of 10mV. The reversal potential of GABAergic currents (E GABA ) was determined from the current-voltage relation obtained by sequentially clamping the membrane at different voltage levels. GABA was photolyzed from the a-carboxy-2-nitrobenzyl-caged GABA compound (Tocris, Bristol, UK) using local uncaging as described previously. 28 Briefly, caged GABA (2.5mM) was dissolved in the physiological solution and delivered at a flow rate of 1 to 3 ll/min to the vicinity of the patchclamped cell using an Aladdin Programmable syringe pump (World Precision Instruments) and a syringe with an inner tip diameter of 100 lm. For local photolysis of caged GABA, the 405nm output of an IQ Series laser diode module (Power Technology, Little Rock, AR) was delivered to the slice via a multimode optical fiber through a Leica LUMPlanFl 340 waterimmersion objective. The ultraviolet (UV) beam yielded an uncaging spot of 10 lm in diameter that was focused either at the soma or at the dendrite at a distance of 100 lm from the soma. 27 At each location, current-voltage relationship was determined by varying the holding potential from 290 to 240 mV (in 10mV steps). Duration of UV light stimuli was 50 milliseconds.
IN VIVO ELECTROPHYSIOLOGICAL RECORDINGS.
Scalp electroencephalographic (EEG) recordings were performed in freely moving rats. To implant recording electrodes, rats were anesthetized with 4.5% isoflurane and maintained at 2.5%, placed in a stereotaxic frame, on a heating pad to control body temperature, and prepared for aseptic surgery. A hole was drilled 2mm posterior to and 1.5mm right of the bregma. A screw connected to an EEG transmitter was placed in the skull, and a reference electrode was placed rostrally in the cerebellum. The screws were attached to the skull with dental cement and the scalp was closed. After surgery, rats were kept warm and received saline (0.9% NaCl, s.c.), and analgesic buprenorphine (0.03mg/kg, s.c.) was administrated to minimize animal pain after surgery. After a 24-hour recovery, EEG (amplified 3 1,000, filtered at 0.16-97Hz pass, acquired at 500Hz) was monitored using a telemetric system (Data Sciences International, St. Paul, MN) for 5 days, 24 hours per day; food and water were given ad libitum. Recordings were analyzed offline using Spike2 version 8.0. Tonic seizures were defined on the EEG as single or multiple 5 to 30Hz polyspikes of 5-fold standard deviation amplitude and 10-to 30-second duration. 13 Statistical Analysis Data were expressed as mean 6 SEM. Statistical analyses were performed using Prism (v6.01; GraphPad Software, San Diego, CA). For comparison between groups with normal distribution, the 2-sample unpaired or paired Student t test was used for 2 groups. When data were not normally distributed, the Mann-Whitney rank sum test (for unpaired data) or the 2-sample KolmogorovSmirnov rank sum test (for paired data) was used. The 1-way analysis of variance all-Tukey test was used to compare multiple groups.
Results

NKCC1 and KCC2 Expression Is Altered at Day 5 Post-SE
The expression of NKCC1 and KCC2 is known to be altered in TLE. [18] [19] [20] [21] [22] However, the temporal changes of these chloride transporters at early stages after SE remain elusive. We found that mRNA transcripts extracted from in toto hippocampi display an initial upregulation of NKCC1 and downregulation of KCC2 at day 1 post-SE (d1pSE) that returns to control levels at d14pSE ( Fig 1A; NKCC1: control, 1 6 0.11; d1, 2.10 6 0.41, p < 0.05; d5, 1.09 6 0.02; d14, 0.95 6 0.2; KCC2; control, 1 6 0.28; d1, 0.46 6 0.02, p < 0.05; d5, 0.73 6 0.10; d14, 1.16 6 0.35).
Using Western blotting, we found that the NKCC1 protein levels were significantly increased by 45% and 70% of control levels at d1pSE and d5pSE, respectively, with no significant alteration at d14pSE (see Fig 1B; control, 1 6 0.08; d1, 1.45 6 0.13, p < 0.01; d5, 1.70 6 0.24, p < 0.05; d14, 1.62 6 0.36, when normalized to b3-tubulin and control, 1 6 0.13; d1, 1.29 6 0.12, p < 0.01; d5, 2.07 6 0.22, p < 0.05; d14, 1.23 6 0.41, when normalized to a-tubulin) when normalized to either a-tubulin or b3-tubulin. In contrast, the neuron-specific KCC2 protein was significantly reduced to 60% of the control levels at d5pSE with a tendency to a partial recovery at d14pSE (see Fig 1C; control, 1 6 0.09; d1, 1.10 6 0.17; d5, 0.58 6 0.08, p < 0.01; d14, 0.77 6 0.16).
Immunohistochemistry toward KCC2 in pilocarpinetreated rat sections showed a preferential cytoplasmic immunoreactivity pattern at d1pSE, with a tendency to return to control conditions at d14pSE but with lower fluorescence intensity (see Fig 1D, E) . This is in contrast to control conditions, where KCC2 immunolabeling showed a strong perisomatic pattern. At d5pSE, KCC2 staining was very low and diffuse within the neuron cell bodies. These findings, showing an overall change in KCC2 neuronal distribution, were consistent within the DG, CA3, and CA1 regions (see Fig 1D, E) .
Taken together, our qRT-PCR, immunoblot, and immunofluorescence results demonstrate that the most drastic dysregulation of both NKCC1 and KCC2 expressions occurred at d5pSE.
Bumetanide Functionally Reduces Early Established Ectopic MF Sprouting
A major reorganization of hippocampal network observed in both human patients and animal models of TLE is the ectopic MF sprouting, 7,29-31 a phenomenon partly responsible for the generation of epileptiform activities in human patients and animal models 11, 30 of TLE. However, although extensively studied during the chronic phase, 18, 32 it has been poorly assessed during the early stages after SE. 28, 29 Thus, we asked whether ectopic MF sprouting occurs in parallel to the robust changes in KCC2 and NKCC1 expression observed at d5pSE (see Fig 1) . Immunohistochemical visualization of rMF using SPO staining 13, 33 revealed a marked ectopic band in the molecular layer of DG and strong staining in the granular cell layer in pilocarpine-treated rats at d5pSE, whereas we found no ectopic band stained in control rats (Fig 2A,  arrowheads ; control, 1 6 0.05; d5pSE, 5.05 6 0.04, p < 0.001). Thus, these results demonstrate that the ectopic MF sprouting is established at d5pSE, correlating with the pathological KCC2 and NKCC1 expression pattern.
We next asked whether abnormal chloride homeostasis might be involved in the early establishment of the ectopic MF sprouting. To achieve this, we use bumetanide to functionally block NKCC1. Because its blood-brain barrier penetration has been challenged, 34, 35 we infused bumetanide at a dose of 20 lM, in accordance with previous pharmacokinetic studies, 36, 37 intracerebrally and continuously from d2pSE to d5pSE, using osmotic minipumps (see Fig 2B) . The curves represent the plot profile of KCC2 staining along 10 mm from the nucleus to the external neuropil of the neurons analyzed. Note that in the control condition but not following SE, peak of KCC2 immunofluorescence occurs at the putative membrane location (arrowheads). Data are mean 6 standard error of the mean; p value obtained using t test analysis: *p < 0.05; **p < 0.01, ***p < 0.001. Scale bars are 10 mm for insets and 100 mm for full pictures. a.u.: arbitrary units.
Interestingly, at d5pSE, we observed a 45% decrease in SPO fluorescence intensity in bumetanidetreated rats as compared to the vehicle-treated rats (see Fig 2C; vehicle-treated rats, 5.03 6 0.04 vs bumetanidetreated, 2.83 6 0.049, p < 0.001, normalized to control).
To find out whether this rMF sprouting is functional as early as d5pSE, we performed the antidromic stimulation of the mossy fiber pathway in the CA3b area while recording local field potentials in the DG cell layer (see Fig 2D) . Importantly, we found that the coastline index
Kourdougli et al: GABA and Glu-ergic Rewiring of the evoked population burst was strongly reduced in bumetanide-treated rats as compared to vehicle-treated pilocarpine rats (vehicle-treated vs bumetanide-treated, 14,326.31 6 3,853 vs 5,252.66 6 1,608, p < 0.05).
Together these results demonstrate that a functional recurrent MF network is already in place at d5pSE. Strikingly, the use of bumetanide in vivo functionally reduced this ectopic MF sprouting.
Bumetanide Blocked NKCC1 Upregulation and Rescued KCC2 Function at d5pSE Several in vitro and in vivo studies have shown that bumetanide can affect the functional expression of NKCC1. 20, 21 To better understand the mechanism by which bumetanide reduced the ectopic MF sprouting and its aberrant network activity, we examined the effect of bumetanide on NKCC1 and KCC2 expression and function. Here, we show that intracerebral infusion of bumetanide partially blocked NKCC1 upregulation. Surprisingly, total KCC2 expression levels were fully restored in bumetanide-treated pilocarpine rats as compared to vehicle-treated rats ( Fig 3B; NKCC1: vehicle-treated rats, 2.28 6 0.10 vs 1.68 6 0.14, p < 0.05, normalized to control; KCC2: vehicle-treated vs bumetanide-treated rats, 0.47 6 0.15 vs 1.40 6 0.23, p < 0.05, normalized to control). Using histological analysis, we show that KCC2 displays a preferentially perisomatic staining in bumetanide-treated rats similar to vehicle-treated rats at d5pSE in the DG, CA3, and CA1 regions (see Fig 3D) . We next investigated whether bumetanide also restored KCC2 function. To investigate KCC2 ability to extrude Cl 2 , we used the whole-cell patch-clamp approach coupled to GABA uncaging in hippocampal slices in the CA1 region (see Fig 3E) . The approach consists of inducing a somatic load of chloride through the patch pipette followed by uncaging of GABA at the soma and at a distance of 100 lm in the apical dendrite.
In vehicle-treated rats, we observed that the E GABA gradient was significantly smaller (20.12 6 0.005mV/ 100 lm) than in bumetanide-treated rats at d5pSE (20.17 6 0.007mV/100 lm). The latter was almost identical to the levels previously measured for this age. 27 Although there is ample evidence for the specificity of bumetanide as an inhibitor of NKCC1 uptake activity, when used at low concentration, the effect observed could be derived from nonspecific action of this compound due to tissue accumulation. Interestingly, high concentration of bumetanide (100 mM) exacerbated the KCC2 downregulation observed at d5pSE (Fig 4; DG: vehicle-treated rats, 0.44 6 0.09 vs bumetanide 20 lMtreated, 0.71 6 0.1; p < 0.01 vs bumetanide 100 lMtreated, 0.44 6 0.08, p < 0.001; CA3: vehicle-treated rats, 0.31 6 0.12 vs bumetanide 20 lM-treated, 0.53 6 0.12, p < 0.001 vs bumetanide 100 lM-treated, 0.01 6 0.11, p < 0.001; and CA1: vehicle-treated rats, 0.60 6 0.10 vs bumetanide 20 lM-treated, 0.81 6 0.13, p < 0.01 vs bumetanide 100 lM-treated, 0.35 6 0.11, p < 0.001). This result shows that nonspecific effects due to either accumulation of bumetanide or derived inhibition of KCC2 would result in opposite effects. Our findings show that intracerebral bumetanide infusion in rats from d2pSE to d5pSE at low concentration is specific and able to partially block NKCC1 expression, and restored not only KCC2 protein expression but also its function at d5pSE within the hippocampus.
p75
NTR Upregulation Drives the Ectopic MF Sprouting and Is Blocked by Bumetanide We have previously shown that, in axotomized organotypic hippocampal slices, altered NKCC1/KCC2 balance induced p75 NTR upregulation that could be prevented by bumetanide. 25 P75 NTR is also known to play a key role in neurite outgrowth 38, 39 and is crucial for axon ) sprouting is observed in the molecular layer of both ventral and dorsal dentate gyrus (DG) in pilocarpine-treated rats and is absent in control rats (arrowheads). Insets show higher magnification of the region depicted by the white squares. Right: Corresponding quantification of the fluorescence (fluo.) intensity normalized to control condition in arbitrary units. Data are mean 6 standard error of the mean (n 5 3 control rats and n 5 6 pilocarpine-treated for d5pSE); ***p < 0.001, with p values obtained using t test analysis. Scale bar represents 150 mm. (B) Experimental paradigm design. Bumetanide or vehicle solutions are infused intracerebrally from d2pSE to d5pSE using osmotic minipumps, and experiments are performed at d5pSE. SE 5 status epilepticus. (C) SPO staining revealed an ectopic rMF band in the molecular layer of the DG in vehicle (Veh)-treated rats that was strongly reduced in bumetanide (Bum)-treated rats and absent under the control condition (arrowheads). Pilo 5 pilocarpine. Insets show higher magnification of the region depicted by the white squares. Corresponding quantification of the fluorescence intensity of synaptoporin in vehicle-and bumetanide-treated d5pSE rats normalized to control condition is shown (n 5 3 for control rats; n 5 5-6 vehicleand bumetanide-treated rats). Scale bar represents 150 mm; ***p < 0.001, using Tukey multiple-comparison test 2-way analysis of variance. (D) Top: Scheme of hippocampal slice with the CA3c-DG antidromic stimulation protocol. Traces are averages of 100 sweeps in both conditions. The arrow shows an antidromic population spike followed by a burst (arrowhead). E stim 5 stimulation electrode in CA3c region; E rec 5 recording electrode in DG cell layer. Bottom: Corresponding bar graph represents the mean coastline burst index observed in slices from vehicle and bumetanide-treated d5pSE rats (n 5 3-4 rats for vehicle-or bumetanide-treated rats). *p < 0.05, using 2-sample Kolmogorov Smirnov test.
formation in the DG under physiological conditions. 40 Therefore, we asked whether bumetanide could regulate p75 NTR expression to mediate the effects observed on the ectopic MF sprouting at d5pSE (Fig 5) . Using Western blot from in toto hippocampi, we found that p75 NTR expression level was reduced in bumetanide-treated rats as compared to vehicle-treated rats at d5pSE (vehicletreated vs bumetanide-treated rats, 1.42 6 0.13 vs The data are normalized to control and expressed relative to b3-tubulin levels (n 5 4-6 per group). (D) Left: KCC2 staining (red) in dentate gyrus (DG; top), cornu ammonis 3 (CA3; middle), and CA1 (bottom) regions in control, vehicle-treated d5pSE, and bumetanide-treated d5pSE rats (n 5 3 for control, n 5 5-6 for vehicle-or bumetanidetreated). Scale bar represents 100 mm. Right: Average curve profile of KCC2 staining in DG, CA3, and CA1 regions at different days post-SE in vehicle-and bumetanide-treated rats. The curves represent the plot profile of KCC2 staining along 10 mm from the nucleus to the external neuropil of the neurons analyzed in control (black), vehicle-treated (blue), and bumetanide-treated (red) conditions. Notice that KCC2 intensity and pattern expression recovered to control conditions following bumetanide application, as shown by the images and plot profile. a.u. 5 arbitrary units. (E) Left: The scheme represents the whole-cell patch-clamp recordings of uncaging c-aminobutyric acid type A (GABA A )-mediated currents (I GABA ) and DE GABA between soma and dendrite of a pyramidal neuron from the CA1 region with an artificially imposed somatic Cl 2 load. E GABA 5 GABA reversal potential; E rec 5 recording electrode; UV 5 405nm light stimuli for GABA uncaging (50 milliseconds). Representative currents of the soma and dendrites are shown following UV-induced GABA uncaging. Middle: The I/V curve obtained in neurons from vehicle-treated (blue curves) or bumetanide-treated (red curves) animals at d5pSE. The arrows show that the soma-to-dendrite gradient is greater following in vivo bumetanide application. Insets show the current following UV light (line) in dendrites (upper panel) and soma (lower panel). V m 5 resting membrane potential. Right: Bar graph represents the quantification of the imposed soma-to-dendrite DE GABA under vehicle-and bumetanide-treated conditions at d5pSE (n 5 3-4 per group). Data are mean 6 standard error of the mean; *p < 0.05, *** p < 0.001, with p value obtained using 2-way analysis of variance in (B-D) and Mann-Whitney U test in (E). 0.90 6 0.13, p < 0.05, normalized to control, 1 6 0.09). Then, using immunohistochemistry, we showed that as previously described, 40, 41 p75 NTR was expressed at a low level in DGCs in control conditions. Interestingly, bumetanide application strongly reduced the SE-induced abnormal p75 NTR expression within the granule cells at d5pSE
(vehicle-treated vs bumetanide-treated rats, 1.64 6 0.04 vs 1.14 6 0.02, p < 0.001, normalized to control). Finally, to establish whether p75 NTR upregulation is involved in the formation of ectopic MF sprouting, we decided to infuse intracerebrally a previously validated 24 p75 NTR functionally blocking antibody (p75 NTR -Ab) from d2pSE to d5pSE (see Fig 5D for the experimental design). Interestingly, SPO staining revealed significantly decreased fluorescence intensity in p75 NTR -Ab-treated as compared to vehicle-or IgG-treated rats at d5pSE (see Fig 5D; IgG-treated rats, 6.27 6 0.57; vehicle-treated vs p75 NTR -Ab-treated rats, 5.06 6 0.5 vs 3.17 6 0.24, p < 0.001, normalized to control).
Altogether, these results suggest that bumetanidemediated functional reduction of ectopic MF sprouting is, at least partly, mediated by p75 NTR upregulation blockade in vivo at d5pSE in the pilocarpine model of TLE.
Early Bumetanide Infusion Reduced Seizure Frequency during the Chronic Phase of TLE The transient application of bumetanide had profound positive effects on morphological and functional reorganization as well as on functional expression of chloride homeostasis regulatory proteins within the hippocampal formation during the early post-SE window.
To examine whether transitory application of bumetanide early after SE had long-lasting effects, we used a similar approach to the one used above with the difference that sprouting is analyzed during the chronic and not the early phase of TLE (Fig 6) . The examination of the cortical EEG (24 h/day) from d2pSE to d5pSE NTR is performed at d5pSE. Bottom: p75 NTR immunostaining performed in dentate gyrus (DG) of control, vehicle-treated, and bumetanide-treated rats. Granular cells are p75 NTR positive (arrowheads), and immunoreactivity surrounds the granular cell layer in the control, vehicle, and bumetanide conditions. Corresponding fluorescence (fluo.) intensity quantification is shown by the bar graph in arbitrary units; values are normalized to control (n 5 3 for control, n 5 4-6 for vehicle-or bumetanide-treated rats). (D) Top: Illustration of experimental procedure. Intracerebral infusion of blocking p75 NTR antibody performed from d2pSE to d5pSE and analysis of the ectopic MF sprouting at d5pSE are shown. Bottom: Synaptoporin (SPO) revealed an ectopic MF band in the molecular layer of the DG in vehicleand IgG-treated rats that was faint in p75 NTR antibody-treated rats (arrowheads). Corresponding quantification of the fluorescence intensity is normalized to the control condition (n 5 3 for control, n 5 4-6 for vehicle-or bumetanide-treated rats). Data are mean 6 standard error of the mean; *p < 0.05, ***p < 0.001, with p values obtained using Tukey multiple-comparison test 2-way analysis of variance. Scale bars represent 150 mm.
did not reveal interictal and ictal activities under the present experimental conditions in vehicle or bumetanideinfused animals (data not shown). However, following bumetanide infusion from d2pSE to d5pSE, SPO staining revealed a reduction of the ectopic band in the molecular layer of DG in bumetanide-treated rats as compared to vehicle-treated rats at 2 months post-SE (vehicle-treated vs bumetanide-treated, 7.34 6 0.35 vs 6.11 6 0.41, p < 0.05, normalized to control). This interesting long-lasting effect of bumetanide on ectopic MF sprouting prompted us to analyze the seizure activity with telemetric scalp EEG recordings at 2 months post-SE after the rats underwent the same experimental paradigm as in the previous experiments. In this chronic condition, we observed that the number of ictal events was reduced by 50% in the bumetanide-treated group as compared to the vehicle-treated group (vehicle-treated vs bumetanide-treated, 13.94 6 0.74 vs 7.05 6 0.39, p < 0.05, normalized to control), without a significant change in their duration (vehicle-treated vs bumetanidetreated, 18.59 6 0.71 vs 17.65 6 1.04, p > 0.05).
Discussion
Studies on TLE show that a major glutamatergic circuit reorganization within the DG, the ectopic rMF, is responsible for an increase in hippocampal excitability and recurrent seizures. 1, 42 Equally strong evidence has been found showing that adult seizures are generated in a circuit in which GABA A receptor (GABA A R)-mediated inhibition is impaired. 20, 43 Within this context, compromised GABAergic inhibition resulting from chloride homeostasis dysregulation in epileptic-like conditions has been extensively studied in both animal models and human resections in TLE. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In these studies, acute use of bumetanide, leading to restoration of chloride homeostasis, has been shown to have potent anticonvulsant effects in the adult brain. However, whether GABAergic depolarization plays a role in the precipitating events of epileptogenesis and could exert long-term effect on morphological and functional features of glutamatergic network rewiring and subsequently affect seizure activity has not been assessed. Here, we have addressed these issues by using a pilocarpine model of TLE. First, we found that early ectopic rMF sprouting and subsequent rMFdriven network aberrant activity were established as early as 5 days after the SE. This timepoint coincided with NKCC1 upregulation and KCC2 downregulation. Importantly, we showed that functional inhibition of NKCC1 with the loop diuretic bumetanide from d2pSE to d5pSE resulted in restoration of chloride homeostasis and robust attenuation of rMF-driven network activity during early epileptogenesis. These effects extended to the chronic epileptic phase and resulted in strongly reduced seizure frequency. The mechanism appears to involve upregulation of the pan-neurotrophin receptor p75 NTR , as inhibition of NKCC1 activity significantly reduced the SE-induced upregulation of this receptor. Previous studies have suggested the involvement of NGF/ TrkA/p75 NTR signaling in MF sprouting in a kindling animal model. 16 We now also demonstrate that p75 NTR is a key factor in the early establishment of the ectopic rMF sprouting in TLE, as: (1) in accordance to previous studies, 44,45 p75 NTR is upregulated at d5pSE; (2) although bumetanide strongly reduced the ectopic rMF sprouting, it also blocked p75 NTR upregulation; and (3) a functionally blocking p75 NTR antibody reduced the ectopic rMF sprouting. Furthermore, previous reports suggest a role of GABA A R-mediated depolarization on axonal elongation during development and adult neurogenesis. 46 Our results show that early post-SE bumetanide application reduces ectopic rMF, p75 NTR expression, and chronic seizures. These effects are associated with impairment of GABA A R-mediated depolarization by bumetanide through its specific inhibitory action on the chloride cotransporter NKCC1. Future investigations are required to elucidate the causal relationship between altered GABAergic transmission and aberrant neurotrophin signaling under pathological conditions. The reported results also suggest that the ectopic MF sprouting, promoted by chloride homeostasis dysregulation and p75 NTR signaling pathway during early epileptogenesis, plays a key role in the development of chronic seizures, because post-SE application of bumetanide reduced the number of spontaneous and recurrent seizures in chronic epileptic rats. It is plausible that the effects exerted by bumetanide are mediated through an effect on post-SE remnant seizure activity. Bumetanide has been shown to have anticonvulsant action in numerous seizure models. 23 Within the early period following SE (2-3 days post-SE), sporadic remnant interictal and ictal activities can occur. 26, 47 However, in the present experimental paradigm, the pilocarpine-treated rats exhibit a seizure-free period from d2pSE to d5pSE (data not shown). Nonetheless, we cannot exclude an effect of bumetanide on sporadic hippocampal interictal events that could not be reliably detected from cortical EEG recordings in contrast to seizure activity. Further studies are necessary to determine whether and how GABA depolarization is involved in post-SE network activity during early epileptogenesis. Altogether, the present study suggests that SEinduced depolarizing GABAergic signaling could play a mechanistic role in the early and long-lasting rewiring of glutamatergic networks that is implicated in the severity of chronic seizures. These results also prompt investigation of optimal conditions for better and more efficient restriction of seizures in the chronic phase using this approach.
In the clinical setting of symptomatic and unprovoked epilepsy, the use of antiepileptic drug prophylaxis during the acute period following SE is recommended. 49, 50 In addition, symptomatic epilepsy especially involving the temporal lobe often displays pharmacoresistance to available antiepileptic drugs. Thus, the results presented here prompt us to conclude that normalizing chloride homeostasis with the US Food and Drug Administration-approved drug bumetanide during the acute post-traumatic period could be able to sustainably reduce pathological glutamatergic network rewiring and subsequent chronic adult epilepsy. Moreover, prophylactic approaches to correct dysregulation of GABAergic transmission and p75 NTR signaling are novel clinically relevant targets that could complement the current therapy following acute symptomatic seizures.
